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Abstract
The extracellular matrix in the lung must be destroyed for Mycobacterium tuberculosis—the 
agent that causes tuberculosis (TB)—to spread.  The current paradigm proposes that this 
destruction occurs as a result of the action of pro-inflammatory cytokines, chemokines, 
immune cells, and lipids that mediate TB-associated necrosis in the lung.  However, this view 
neglects the fact that lung matrix can only be degraded by proteases.  We propose an original 
conceptual framework of TB immunopathology that may lead directly to treatments that 
involve inhibition of matrix metalloproteinase activity to hinder matrix destruction and 
thereby reduce the morbidity and mortality associated with TB. 
INTRODUCTION
Tuberculosis, an infectious disease caused by Mycobacterium tuberculosis (Mtb), affects 
about one third of the world's population (1). Although most infections are asymptomatic, 
active tuberculosis, usually primarily involving the lungs, is often fatal .  Despite the 
intensive biomedical research efforts of the last two decades, the standard TB treatment 
regime has remained unchanged for over 30 years.  Although it is widely accepted that 
immunopathology—that is, an excessive host immune response to mycobacterial antigens—
causes mortality in patients (2), and also drives the destruction of the extracellular matrix that 
is necessary for the spread of M. tuberculosis (Mtb), understanding of this process remains
surprisingly vague (3).  A contributing factor is the imprecise terminology used to describe 
TB-related tissue damage, such as "immunopathology," "delayed-type hypersensitivity" (a
secondary, cell-mediated immune reaction that occurs several days after antigen exposure),
and "caseous necrosis" (the accumulation of amorphous debris characteristic of TB 
infection). Patients die from this TB-associated immunopathology, which often worsens 
during initial treatment and so mortality continues even after starting effective 
antituberculous agents.  Fear of driving pathology also prevents the development of 
immunostimulatory strategies to reduce treatment duration from the current minimum of 6 
months.  Therefore, we need a better understanding of the mechanisms of TB-related 
pathology to reduce deaths from TB and to introduce short course treatment regimes.
HISTORIC TERMINOLOGY OF TB PATHOLOGY
TB is primarily a disease of the lung, which has an intricate structure of air-filled 
alveoli to permit gas exchange. Mtb is phagocytosed by macrophages, the central effector 
cells of the innate immune response. The microscopic pathology caused by Mtb in humans 
has been described as caseous necrosis for over 100 years, because of the accumulation of 
material with a cheese-like appearance in the center of TB-associated granulomas (cell 
aggregates—in which lymphocytes surround infected macrophages—that are thought to form 
to isolate Mtb).  Lung infection leads to cavitation, which is the development of large air-
filled spaces within the lung where the intricate parenchymal structure has been completely 
destroyed (Fig. 1).  Mtb then proliferates exponentially in the cavity, essentially walled off 
from the host immune response (4), and each cavity may contain up to 109 mycobacteria (5).
The current paradigm of TB pathology states that accumulating caseous material erodes into 
an airway, creating a cavity within which the Mtb proliferates freely (Fig. 2, black arrows).   
This paradigm was developed from the rabbit model during seminal work in the 1960s by 
Lurie and Dannenberg, and they highlighted the likely involvement of proteases, lipases and 
nucleases (6).  However, in current TB reviews the involvement of proteases is completely 
neglected (2-3, 7-10). The observation from a series of post-mortem studies that human 
cavities appear to begin in areas of lipoid pneumonia (regions of lung inflammation caused 
by the presence of lipid-rich material), not in well organised granulomas, has generally been 
overlooked (11). More recent conceptual models of TB imunopathology propose an 
imbalance between TH1 and TH2 responses (two types of T helper cells) (12), excessive 
production of interleukin-17 (13), a cytokine that induces proinflammatory responses, or a 
failure of regulatory T cells to limit immunopathology (14), but none address effector 
mechanisms of tissue damage.
All of these models overlook the fact that cavity formation must involve destruction 
of the lung extracellular matrix, which includes a complex, highly stable network of collagen 
fibrils (15) that supports the structure of the lung and that, when intact, regulates many 
aspects of inflammation (16).  Matrix breakdown has historically been considered part of a 
single process of caseous necrosis (8), but the death of cells to cause caseation is likely to be 
a distinct process from extracellular matrix destruction (Fig. 2, red arrows).  Indeed, the
network of collagen fibrils can only be degraded by proteases. The cytokines, chemokines, T 
cells, and lipids that have been proposed as the mediators of caseous necrosis simply cannot 
degrade fibrillar collagens, the primary structural fibrils of the lung (15). The inescapable 
conclusion is that matrix destruction that leads to lung cavitation in TB must result from 
protease activity.    
LUNG MATRIX BIOCHEMISTRY PREDICTS A CENTRAL ROLE FOR 
METALLOPROTEASES
The human lung has evolved to be highly resistant to destruction of the extracellular 
matrix; for example, even after exposure to cigarette smoke for a lifetime, the majority of 
smokers have preserved lung function (17). Mtb must overcome this matrix protective 
environment to degrade the lung fibrils to permit transmission.  Consequently, understanding 
the processes that drive destruction of the lung extracellular matrix is central to understanding 
TB immunopathology.  Lung fibrillar collagens are only cleaved at neutral pH by the matrix 
metalloproteinases (MMPs) (18),  a family of proteases that are collectively able to degrade 
all components of the extracellular matrix.  MMPs are not stored in cells, except neutrophils,
and their expression is tightly regulated at the level of gene transcription (19).  Therefore, 
MMPs must be directly induced by Mtb as opposed to their protease activity being a by-
product of cellular necrosis.  Accumulating evidence implicates MMP activity in TB-related 
tissue destruction.  For example, it was demonstrated in the 1970s that mycobacterial 
stimulation of guinea pig macrophages up-regulates collagenase expression (20). Virulent 
Mtb up-regulates MMP-1 (interstitial collagenase) more potently than the weakened vaccine 
strain M. bovis BCG in primary human macrophages (21).  In patients with TB, pulmonary 
epithelial cells and fibroblasts express MMP-1, regulated by a monocyte-dependent network 
(22-23). In the zebrafish model of TB, M. marinum up-regulates epithelial cell MMP-9
secretion to generate a migration gradient for monocytes (24).  Additionally, virulent M. 
marinum up-regulates collagenases more potently than an attenuated strain (25).
The mouse is the most widely used model of TB immunology, with key roles for 
CD4+ helper T cells, interferon-????????????????????????????-?????????????????????? ??????
studies subsequently confirmed in man (2, 26). However, when infected with Mtb the mouse 
does not develop immunopathology similar to that in humans.  Alveolar walls remain intact 
in areas of infection (26) and the mouse does not express an ortholog of MMP-1 in the lung 
(27-28). Therefore, the mouse cannot be used to study MMP-1 driven matrix destruction in 
TB and reliance on this model may have limited progress in understanding TB 
immunopathology.  Despite the biochemical arguments for a central role for MMPs in TB 
pathology and the evidence that they play a role in destroying the lung matrix, translation to 
new therapies for TB has thus far been slow.
A NEW CONCEPTUAL FRAMEWORK OF TB IMMUNOPATHOLOGY
TB immunopathology is currently considered under the umbrella term of caseous 
necrosis, but it should be divided into fundamental processes.  At least 3 mechanisms must be 
taking place to cause the immunopathology that results in caseous necrosis.  First, Mtb 
infection is directly toxic to macrophages and causes cell necrosis (29).  Second, several lines 
of evidence demonstrate that activated T-cells drive pathology (2).  For example, in advanced 
HIV infection during which patients present with TB in the context of a low CD4+ cell count, 
caseating granulomas are not observed (2), but as the immune system reconstitutes during 
anti-retroviral therapy, pathology develops (30).  Likewise, in the rabbit model, pre-
sensitisation with serial injections of heat killed M. bovis to drive a delayed type 
hypersensitivity response in the skin accelerates pathology and results in cavitation in the 
lungs (31).  Third, MMP activity must be a final effector causing destruction of the 
extracellular matrix.  Considering these processes separately permits evaluation of where 
therapies can be most effectively targeted to limit immune-mediated tissue damage.
THE URGENT CLINICAL NEED TO LIMIT IMMUNOPATHOLOGY
TB continues to kill almost 2 million people per year (1) and these patients die from 
TB-related tissue destruction.  Furthermore, the introduction of new anti-tuberculous drugs 
with rapid bactericidal activity, such as TMC207 (32), will increase the early release of Mtb 
antigen and consequently drive pathology.  Ironically, very rapid killing of the pathogen may 
also kill the host if the mycobacterial load is high.  Similarly, the early introduction of anti-
retroviral therapy for patients with TB-HIV co-infection, which reduces mortality, will 
increase incidence of TB immune reconstitution inflammatory syndrome, which is 
characterised by tissue destruction (30). (This condition occurs when the immune system 
begins to recover and responds to Mtb infection, paradoxically causing worsening pathology
New approaches to limit TB-related immunopathology, both in cavitatory and disseminated 
TB, are needed to reduce mortality and to permit immunostimulatory approaches to shorten 
treatment.  If one breaks down TB pathology into its constitutive parts, MMPs emerge as the 
immunopathological mediators most readily targeted with orally available compounds.  
MMP INHIBITION TO REDUCE IMMUNOPATHOLOGY IN TB
If MMPs are proven to be the final common effectors of matrix destruction in TB, 
MMP inhibition emerges as an attractive strategy to limit TB morbidity and mortality.  Many 
MMP inhibitors were developed in the 1990’s as they showed initial promise in the treatment 
of cancer (33).  Although results of the first trials in that clinical context were disappointing,
in part because of musculoskeletal side-effects, more selective inhibitors are now available.  
In addition, MMP inhibition in TB would be of relatively short duration.  Tetracycline
antibiotics are broad spectrum MMP inhibitors, acting both at a pre-transcriptional level and 
also directly as enzyme inhibitors (34). Doxycycline (a type of tetracycline), prescribed at a 
sub-antimicrobial dose of 20 mg twice a day, is licensed by the U.S. Food and Drug 
Adminstration to limit MMP activity in periodontal disease (35).  Doxycycline is cheap, safe, 
and widely available, so could be readily deployed in resource poor settings.  A more potent, 
selective collagenase inhibitor, Ro32-3555, has passed phase III clinical trials for patients 
with arthritis (36), and so has the potential to prevent lung matrix destruction.  Other MMP 
inhibitors have been developed that would merit study in appropriate animal models of TB 
(34).  A central question is whether a specific MMP should be targeted or whether broad-
spectrum MMP inhibition will be more efficacious.  
In summary, extracellular matrix destruction is one of the critical pathological events
in TB.  Defining mechanisms of TB immunopathology identifies MMP activity as a potential 
therapeutic target to limit morbidity and mortality in TB.
Fig. 1: Matrix destruction. (A) Normal lung architecture is highly organised, supported by 
an intricate network of extracellular matrix. About 170 alveoli are present per cubic 
millimeter of healthy lung tissue in humans (B) This matrix is destroyed during TB, resulting 
in for formation of cavities that are often several centimeters across (black arrow on 
computerized tomography scan).  
Fig. 2: Lung cavitation must result from extracellular matrix destruction.  The 
longstanding paradigm of TB immunopathology (black arrows) states that cell death  leads to 
the accumulation caseous necrosis in TB granulomas (arrowheads), which then rupture into 
an airway, causing an air-filled cavity in the lung (white arrow on chest radiograph).  This 
model does not explain how the extracellular matrix is degraded.   We propose that two 
independent processes must be taking place: (A) cell death causing the accumulation of 
caseous material and (B) induction of protease activity to drive destruction of the 
extracellular matrix which then results in cavity formation and transmission (red arrows).
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